| Autor: |
Pultar, Joseph, Wadowski, Patricia P., Panzer, Simon, Gremmel, Thomas |
| Zdroj: |
VASA Zeitschrift fuer Gefaesskrankheiten; 20240101, Issue: Preprints p1-12, 12p |
| Abstrakt: |
Abstract.Antiplatelet agents significantly reduce mortality and morbidity in ischemic heart disease, cerebrovascular disease and peripheral artery disease (PAD), and are therefore part of guideline-driven daily medical treatment in these patients. Due to its beneficial effects in the secondary prevention of atherothrombotic events, aspirin remains the most frequently prescribed antiplatelet agent in cardiovascular disease. In patients with acute coronary syndromes (ACS) and in those undergoing angioplasty with stent implantation dual antiplatelet therapy with aspirin and an adenosine diphosphate (ADP) receptor antagonist is indicated. The development of the newer ADP P2Y12inhibitors prasugrel and ticagrelor has further improved prognosis in ACS patients compared to clopidogrel. Moreover, vorapaxar allows the inhibition of platelet activation by thrombin via protease-activated receptor-1 and has been approved for the use in patients with PAD and in those with a history of myocardial infarction. This review article summarizes the current evidence on oral antiplatelet agents in cardiovascular disease.Keywords:Aspirin, clopidogrel, prasugrel, ticagrelor, vorapaxar, cardiovascular disease |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
